FDG-PET staging and importance of lymph node SUV in head and neck cancer

Head and Neck Oncology

Volumn 2, Issue 1, 2010, Pages

  Kubicek, Gregory J ^a,b,c   Champ, Collin ^a   Fogh, Shannon ^a,d   Wang, Fen ^b   Reddy, Eashwer ^b   Intenzo, Charles ^a   Dusing, Reginald W ^b   Machtay, Mitchell ^a,e  

^a THOMAS JEFFERSON UNIVERSITY HOSPITAL   (United States)

^b UNIVERSITY OF KANSAS MEDICAL CENTER   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

^d UNIVERSITY OF SAN FRANCISCO   (United States)

^e UNIVERSITY HOSPITALS OF CLEVELAND   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

FLUORODEOXYGLUCOSE; DIAGNOSTIC AGENT; FLUORODEOXYGLUCOSE F 18; RADIOPHARMACEUTICAL AGENT;

ADULT; ARTICLE; CANCER RECURRENCE; CANCER STAGING; CONTROLLED STUDY; DIAGNOSTIC IMAGING; DIAGNOSTIC VALUE; FEMALE; FOLLOW UP; HEAD AND NECK CANCER; HEAD AND NECK SURGERY; HUMAN; INTERMETHOD COMPARISON; LYMPH NODE; MAJOR CLINICAL STUDY; MALE; OVERALL SURVIVAL; POSITRON EMISSION TOMOGRAPHY; PRIMARY TUMOR; PRIORITY JOURNAL; PROGNOSIS; RETROSPECTIVE STUDY; SENSITIVITY AND SPECIFICITY; TUMOR VOLUME; CLINICAL TRIAL; DISEASE FREE SURVIVAL; HEAD AND NECK TUMOR; LYMPH NODE METASTASIS; METABOLISM; METHODOLOGY; MIDDLE AGED; MULTICENTER STUDY; PATHOLOGY; SCINTISCANNING;

DISEASE-FREE SURVIVAL; FEMALE; FLUORODEOXYGLUCOSE F18; HEAD AND NECK NEOPLASMS; HUMANS; LYMPH NODES; LYMPHATIC METASTASIS; MALE; MIDDLE AGED; NEOPLASM STAGING; POSITRON-EMISSION TOMOGRAPHY; PROGNOSIS; RADIOPHARMACEUTICALS; RETROSPECTIVE STUDIES;

EID: 77955343932     PISSN: None     EISSN: 17583284     Source Type: Journal    
DOI: 10.1186/1758-3284-2-19     Document Type: Article

References (36)

1. Cancer statistics, 2008. A Jemal R Siegal R Ward Y Hao J Xu T Murray MJ Thun, CA Cancer J Clin 2008 58 71 96 10.3322/CA.2007.0010 18287387
2. The chemoradiation paradigm in head and neck cancer. TY Seiwert JK Salama EE Vokes, Nat Clin Pract Oncol 2007 4 156 171 10.1038/ncponc0750 17327856
3. Radiotherapy plus cetuximab for squamous-cell carcinoma of the head and neck. JA Bonner PM Harari J Giralt N Azarnia DM Shin RB Cohen CU Jones R Sur D Raben J Jassem R Ove MS Kies J Baselga H Youssoufian N Amellal EK Rowinsky KK Ang, N Engl J Med 2006 354 567 578 10.1056/NEJMoa053422 16467544
4. PET/CT for the staging and follow-up of patients with malignancies. TD Poeppel BJ Krause TA Heusner C Boy A Bockisch G Antoch, Eur J Radiol 2009 70 382 92 10.1016/j.ejrad.2009.03.051 19406595
5. Use, Accuracy, and Implications for Patient Management of [18F]-2-Fluorodeoxyglucose-Positron Emission/Computerized Tomography for Head and Neck Tumors. AM Zanation DK Sutton ME Couch MC Weissler WW Shockley CG Shores, Laryngoscope 2005 115 1186 1190 10.1097/01.MLG.0000163763.89647.9F 15995504
6. Positron Emission Tomography in the Evaluation of Synchronous Lung Lesions in Patients With Untreated Head and Neck Cancer Arch Otolaryngol Head Neck Surg. MK Wax LL Myers EC Gabalski S Husain JM Gona H Nabi, 2002 128 703 707 12049568
7. Combined 18F-fluorodeoxyglucose-positron emission tomography and computed tomography as a primary screening method for detecting second primary cancers and distant metastases in patients with head and neck cancer. SY Kim JL Roh NK Yeo, Ann Oncol 2007 18 1698 703 10.1093/annonc/mdm270 17716985
8. The value of 18F-FDG PET in the detection of stage M0 carcinoma of the nasopharynx. TC Yen JT Chang SH Ng YC Chang SC Chan KJ Lin WJ Lin YK Fu CY Lin, J Nucl Med 2005 46 405 10 15750151
9. Impact of FDGPET/CT imaging on nodal staging for head-and-neck squamous cell carcinoma. R Murakami H Uozumi T Hirai R Nishimura S Shiraishi K Ota D Murakami S Tomiguchi N Oya S Katsuragawa Y Yamashita, Int J Radiat Oncol Biol Phys 2007 68 377 382 17321066
10. Prospective comparison of 18F-FDG PET with conventional imaging modalities (CT, MRI, US) in lymph node staging of head and neck cancer. S Adams RP Baum T Stuckensen K Bitter G Hör, Eur J Nucl Med 1998 25 1255 1260 10.1007/s002590050293 9724374
11. 18F-FDG PET and CT/MRI in oral cavity squamous cell carcinoma: A prospective study of 124 patients with histologic correlation. SH Ng TC Yen CT Liao, J Nucl Med 2005 46 1136 1143 16000282
12. Evaluation of18 F-fluorodeoxyglucose positron emission tomography and computed tomography with histopathologic correlation in the initial staging of head and neck cancer. A Hannah AM Scott H Tochon-Danguy JG Chan T Akhurst S Berlangieri D Price GJ Smith T Schelleman WJ McKay A Sizeland, Ann Surg 2002 236 208 217 10.1097/00000658-200208000-00009 12170026
13. Prospective study of [18F]fluorodeoxyglucose positron emission tomography and computed tomography and magnetic resonance imaging in oral cavity squamous cell carcinoma with palpably negative neck. SH Ng TC Yen JT Chang JG Chan T Akhurst S Berlangieri D Price GJ Smith T Schelleman WJ McKay A Sizeland, J Clin Oncol 2006 24 4371 6 10.1200/JCO.2006.05.7349 16983105
14. Sentinel node biopsy in oral cavity cancer: Correlation with PET scan and immunohistochemistry. FJ Civantos C Gomez C Duque F Pedroso WJ Goodwin DT Weed D Arnold F Moffat, Head Neck 2003 25 1 9 10.1002/hed.10213 12478537
15. A new approach to pre-treatment assessment of the N0 neck in oral squamous cell carcinoma: The role of sentinel node biopsy and positron emission tomography. NC Hyde E Prvulovich L Newman WA Waddington D Visvikis P Ell, Oral Oncol 2003 39 350 360 10.1016/S1368-8375(02)00121-5 12676254
16. FDG-PET/CT imaging for preradiotherapy staging of head-and-neck squamous cell carcinoma. DL Schwartz E Ford J Rajendran B Yueh MD Coltrera J Virgin Y Anzai D Haynor B Lewellyn D Mattes J Meyer M Phillips M Leblanc P Kinahan K Krohn J Eary GE Laramore, Int J Radiat Oncol Biol Phys 2005 61 129 136 15629603
17. Is there a role for positron emission tomography with 18F-fluorodeoxyglucose in the initial staging of nodal negative oral and oropharyngeal squamous cell carcinoma. SJ Stoeckli H Steinert M Pfaltz S Schmid, Head Neck 2002 24 345 349 10.1002/hed.10057 11933176
18. Impact of 18-F-2-Fluorodeozyglucose-positron emission tomography/computed tomography on previously untreated head and necak cancer patients. AJ Fleming SP Smith CM Saul, Laryngoscope 2007 117 1173 79 10.1097/MLG.0b013e31805d017b 17603315
19. FDG-PET prediction of head and neck squamous cell cancer outcomes. Dl Schwartz J Ragendran B Yueh MD Coltrera M Leblanc J Eary K Krohn, Arch Otolaryngol Head Neck Surg 2004 130 1361 7 10.1001/archotol.130.12.1361 15611393
20. FDG PET studies during treatment: prediction of therapy outcome in head and neck squamous cell carcinoma. E Brun E Kjellen J Tennvall T Ohlsson A Sandell R Perfekt R Perfekt J Wennerberg SE Strand, Head Neck 2002 24 127 135 10.1002/hed.10037 11891942
21. Prediction of survival with fluorine-18-fluorodeoxyglucose and PET in head and neck cancer. H Minn M Lapela PJ Klemi R Grénman S Leskinen P Lindholm J Bergman E Eronen M Haaparanta H Joensuu, J Nucl Med 1997 38 1907 1911 9430467
22. FDG-PET: a possible prognostic factor in head and neck cancer. W Halfpenny SF Hain L Biassoni MN Maisey JA Sherman M McGurk, Br J Cancer 2002 86 512 516 10.1038/sj.bjc.6600114 11870529
23. 2-[18F]-Fluoro-2-deoxy-D-glucose positron emission tomography as guidance for primary treatment in patients with advanced-stage resectable squamous cell carcinoma of the larynx and hypopharynx. JL Roh KH Pae SH Choi JS Kim S Lee SB Kim SY Nam SY Kim, Eur J Surg Oncol 2007 33 790 5 17306956
24. Use of 18F-FDG PET for primary treatment strategy in patients with squamous cell carcinoma of the oropharynx. SY Kim JL Roh MR Kim JS Kim SH Choi SY Nam SW Lee SB Kim, J Nucl Med 2007 48 752 7 10.2967/jnumed.107.039610 17475963
25. Prediction of outcome in head-and-neck cancer patients using the standardized uptake value of 2-[18F]fluoro-2-deoxy-D-glucose. AS Allal DO Slosman T Kebdani M Allaoua W Lehmann P Dulguerov, Int J Radiat Oncol Biol Phys 2004 59 1295 300 15275712
26. Serial positron emission tomography scans following radiation therapy of patients with head and neck cancer. KM Greven DW Williams WF McGuirt Sr BA Harkness RB D'Agostino Jr JW Keyes Jr NE Watson Jr, Head Neck 2001 23 942 6 10.1002/hed.1136 11754497
27. Preoperative [18F] fluorodeoxyglucose positron emission tomography standardized uptake value of neck lymph nodes predicts neck cancer control and survival rates in patients with oral cavity squamous cell carcinoma and pathologically positive lymph nodes. CT Liao JT Chang HM Wang SH Ng C Hsueh LY Lee CH Lin IH Chen SF Huang AJ Cheng TC Yen, Int J Radiat Oncol Biol Phys 2009 74 1054 61 19101096
28. 18-F-Flurodeoxyglucose positron emission tomography to evaluate cervical node metastases in patietns with head and neck squamous cell carcinoma: A meta-analysis. P Kyzas E Evangelou D Denaxa-Kyza JP Ioannidis, J Natl Can Inst 2008 100 712 20 10.1093/jnci/djn125
29. Prognostic Significance of FDG PET for Head and Neck Cancer Treated with IMRT. M Yao T Nguyen KJ Dornfeld, Int J Radiat Oncol Biol Phys 2005 S1 63 149 S150
30. Head and neck malignancy: is PET/CT more accurate than PET or CT alone? B Branstetter T Blodgett L Zimmer CH Snyderman JT Johnson S Raman CC Meltzer, Radiology 2005 235 580 586 10.1148/radiol.2352040134 15858097
31. PET and PET/CT using 18F-FDG in the diagnosis and management of cancer patients. K Endo N Oriuchi T Higuchi Y Iida H Hanaoka M Miyakubo T Ishikita K Koyama, Int J Clin Oncol 2006 4 286 296 10.1007/s10147-006-0595-0 (Pubitemid 44306212)
32. Head and neck cancer: clinical usefulness and accuracy of PET/CT image fusion. H Schoder H Yeung M Gonen D Kraus SM Larson, Radiology 2004 231 66 72 10.1148/radiol.2311030271 (Pubitemid 38375411)
33. Factors associated with severe late toxicity after concurrent chemoradiation for locally advanced head and neck cancer: an RTOG analysis. M Machtay J Moughan A Trotti AS Garden RS Weber JS Cooper A Forastiere KK Ang, J Clin Oncol 2008 26 3582 9 10.1200/JCO.2007.14.8841 18559875
34. Cisplatin and fluorouracil alone or with docetaxel in head and neck cancer. MR Posner Dm Hershock CR Blajman E Mickiewicz E Winquist V Gorbounova S Tjulandin DM Shin K Cullen TJ Ervin BA Murphy LE Raez RB Cohen M Spaulding RB Tishler B Roth C Viroglio Rdel V Venkatesan I Romanov S Agarwala KW Harter M Dugan A Cmelak AM Markoe PW Read L Steinbrenner AD Colevas CM Norris Jr RI Haddad, N Engl J Med 2007 357 1705 15 10.1056/NEJMoa070956 17960013
35. Cisplatin, fluorouracil, and docetaxel in unresectable head and neck cancer. JB Vermorken E Remenar C van Herpen T Gorlia R Mesia M Degardin JS Stewart S Jelic J Betka JH Preiss D van den Weyngaert A Awada D Cupissol HR Kienzer A Rey I Desaunois J Bernier JL Lefebvre, N Engl J Med 2007 357 1695 704 10.1056/NEJMoa071028 17960012
36. Defining risk levels in locally advanced head and neck cancers: a comparative analysis of concurrent postoperative radiation plus chemotherapy trials of the EORTC (#22931) and RTOG (# 9501). J Bernier JS Cooper TF Pajak M van Glabbeke J Bourhis A Forastiere EM Ozsahin JR Jacobs J Jassem KK Ang JL Lefèbvre, Head Neck 2005 27 843 50 10.1002/hed.20279 16161069